Prolactin, growth hormone and the immune system in humans

Cellular and Molecular Life Sciences

Volumn 54, Issue 10, 1998, Pages 1102-1108

  Velkeniers, B ^a   Dogusan, Z ^a   Naessens, F ^a   Hooghe, R ^a,b   Hooghe Peters, E L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b FLEMISH INSTITUTE FOR TECHNOLOGICAL RESEARCH VITO   (Belgium)

Author keywords

Acromegaly; Ageing; AIDS; Growth hormone; Insulin like growth factor; Pituitary adenoma; Prolactin

Indexed keywords

GROWTH FACTOR; PROLACTIN; SOMATOMEDIN C;

AGING; AUTOIMMUNE DISEASE; CATABOLISM; CELL DIFFERENTIATION; CELL GROWTH; CHEMOTAXIS; GRANULOCYTE; HASHIMOTO DISEASE; HORMONE RELEASE; HUMAN; IMMUNE SYSTEM; INFECTION RATE; LYMPHATIC SYSTEM; MACROPHAGE; NATURAL KILLER CELL; PHAGOCYTOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGING; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMAN GROWTH HORMONE; HUMANS; IMMUNE SYSTEM; INSULIN-LIKE GROWTH FACTOR I; PROLACTIN; RECEPTORS, PROLACTIN; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION;

EID: 0031782811     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050239     Document Type: Review

References (75)

1. Gala R. R. (1991) Prolactin and growth hormone in the regulation of the immune system. Proc. Soc. Exp. Biol. Med. 198: 513-526
2. Kooijman R., Hooghe-Peters E. L. and Hooghe R. (1996) Prolactin, growth hormone and insulin-like growth factor-I in the immune system 63: 377-454
3. Clark R. (1997) The somatogenic hormones and insulin-like growth factor-I: stimulators of lymphopoiesis and immune function. Endocr. Rev. 18: 157-179
4. Hooghe-Peters E. L. and Hooghe R. (1995) Growth Hormone, Prolactin and IGF-I as Lymphohemopoietic Cytokines, R. G. Landes. Austin, TX and Springer, New York
5. Auernhammer C. J. and Strasburger C. J. (1995) Effects of growth hormone and insulin-like growth factor I on the immune system. Eur. J. Endocrinol. 133: 635-645
6. Shalet S. M., Toogood A., Rahim A. and Brennan B. M. D. (1998) The diagnosis of growth hormone deficiency in children and adults. Endocr. Rev. 19: 203-223
7. Baumann G. and Maheshwari H. (1997) The dwarfs of Sindh: severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. Acta Paediatr. Suppl. 423: 33-38
8. Takahashi Y., Kaji H., Okimura Y., Goji K., Abe H. and Chihara K. (1996) Brief report: short stature caused by a mutant growth hormone. N. Engl. J. Med. 334: 432-436
9. Laron Z. (1996) Short stature due to genetic defects affecting growth hormone activity. N. Engl. J. Med. 334: 463-465
10. Casanova S., Repellin A. M. and Schimpff R. M. (1990) Production of interleukin-1a and interleukin-2 by mononuclear cells from children with growth delay in relation to the degree of growth hormone deficiency: effects of substitutive treatment. Horm. Res. 34: 209-214
11. Wit J. M., Kooijman R., Rijkers G. T. and Zegers B. J. M. (1993) Immunological findings in growth hormone-treated patients. Horm. Res. 39: 107-110
12. Kiess W., Malozowski S., Gelato M., Butenand O., Doerr H., Crips B. et al. (1988) Lymphocyte subset distribution and natural killer activity in growth hormone deficiency before and during short-term treatment with growth hormone releasing hormone. Clin. Immunol. Immunopathol. 48: 85-94
13. Bozzola M., Valtorta A., Moretta A., Cisternino M., Biscaldi I. and Schimpff R. M. (1990) In vitro and in vivo effect of growth hormone on cytotoxic activity. J. Pediat. 117: 596-599
14. Manfredi R., Tumietto F., Azzaroli L., Zucchini A., Chiodo F. and Manfredi G. (1994) Growth hormone (GH) and the immune system: impaired phagocytic function in children with idiopathic GH deficiency is corrected by treatment with biosynthetic GH. J. Pediat. Endocrinol. 7: 245-251
15. Stewart D. M., Notarangelo L. D., Kurman C. C., Staudt L. M. and Nelson D. L. (1995) Molecular genetic analysis of X-linked hypogammaglobulinemia and isolated growth hormone deficiency. J. Immunol. 155: 2770-2774
16. Smith C. I. E., Islam K. B., Vorechovsky L. Olerup O., Wallin E., Rabbani H. et al. (1994) X-linked agammaglobulinemia and other immunoglobulin deficiencies. Immunol. Res. 138: 159-183
17. Christiansen J. D., Jorgensen J. O., Pedersen S. A., Muller J., Jorgensen J., Moller J. et al. (1991) GH-replacement therapy in adults. Horm. Res. 36 (Suppl. 1): 66-72
18. Span J. P. T., Pieters G. F. F. M., Smals A. G. H., Koopmans P. P. and Kloppenborg P. W. C. (1996) Number and percentage of NK-cells are decreased in growth hormone-deficient adults. Clin. Immunol. Immunopathol. 78: 90-92
19. Bozzola M., Cisternino M., Larizza D., Moretta A., Valtorta A., Schimpff R. M. et al. (1989) Influence of growth hormone (GH) on natural killer (NK) activity in women with impaired endogenous growth hormone secretion. Metabolism 38: 193-195
20. Auernhammer C. J., Feldmeier H., Nass R., Fachmann K. and Strasburger C. J. (1996) Insulin-like growth factor I is an independent coregulatory modulator of natural killer (NK) cell activity. Endocrinology 137: 5332-5336
21. Rappaport R. G. and Bozzola M. (1997) Role of B-cells in growth hormone-immune interactions. Acta Paediatr. Suppl. 423: 82-83
22. Rekers-Mombarg L. T., Rijkers G. T., Massa G. G. and Wit J. M. (1995) Immunologic studies in children with idiopathic short stature before and during growth hormone therapy. Dutch Growth Hormone Working Group. Horm. Res. 44: 203-207
23. Spadoni G. L., Rossi P., Ragno W., Galli E., Cianfarani S., Galasso C. et al. (1991) Immune function in growth hormone-deficient children treated with biosynthetic growth hormone. Acta Paediatr. Scand. 80: 75-79
24. Fornari M. C., Scolnik M. P., Palacios M. F., Intebi A. D. and Diez R. A. (1994) Growth hormone inhibits normal B-cell differentiation and neutrophils chemotaxis in vitro. Int. J. Immunopharmacol. 16: 667-673
25. Parks J. S., Brown M. R. and Faase M. E. (1997) The spectrum of growth-hormone insensitivity. J. Pediatr. 131: S45-S50
26. Rosenfeld R. G., Rosenbloom A. L. and Guevara-Aguirre J. (1994) Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr. Rev. 15: 369-390
27. Iida K., Takahashi Y., Kaji H., Nose O., Okimura Y., Abe H. et al. (1998) Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J. Clin. Endocrinol. Metab. 83: 531-537
28. Bjerkness R., Vesterhus P. and Aarskog D. (1997) Increased neutrophil insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced functional capacity in patients with untreated Laron syndrome. Eur. J. Endocrinol. 136: 92-95
29. Colao A., Merola B., Ferone D. and Lombardi G. (1997) Acromegaly. J. Clin. Endocrinol. Metab. 82: 2777-2781
30. Kotzmann H., Köller M., Czernin S., Clodi M., Svoboda T., Riedl M. et al. (1994) Effect of elevated growth hormone concentrations on the phenotype and functions of human lymphocytes and natural killer cells. Neuroendocrinology 60: 618-625
31. Fornari M. C., Palacios M. F., Diez R. A. and Intebi A. D. (1994) Decreased chemotaxis of neutrophils in acromegaly and hyperprolactinemia. Eur. J. Endocrinol. 130: 463-468
32. Gerli R., Rambotti P., Nicoletti I., Orlandi S., Migliorati G. and Riccardi C. (1986) Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin. Exp. Immunol. 64: 399-406
33. Matera L., Ciccarelli E., Cesano A., Veglia F., Miola C. and Camanni F. (1989) Natural killer activity in hyperprolactinemic patients. Immunopharmacology 18: 143-146
34. Matera L., Cesano A., Bellone G. and Oberholtzer E. (1992) Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B and NK lymphocytes. Brain Behav. Immun. 6: 409-417
35. Clodi M., Svoboda T., Kotzmann H., Deyssig R., Woloszczuk W, Zielinski C. C. et al. (1992) Effect of elevated serum prolactin concentrations on cytokine production and natural killer cell activity. Neuroendocrinology 56: 775-779
36. Vidaller A., Guadarrama F., Llorente L., Mendez J. P., Larrea F., Villa A. R. et al. (1992) Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J. Clin. Immunol. 12: 210-214
37. Morikawa K., Oseko F. and Morikawa S. (1994) Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin. Exp. Immunol. 95: 514-518
38. Corpas E., Harman S. M. and Blackman M. R. (1993) Human growth hormone and human aging. Endocr. Rev. 14: 20-39
39. LeRoith D., Yanowski J., Kaldjian E. P., Jaffe E. S., LeRoith T., Purdue K. et al. (1996) The effects of growth hormone and insulin-like growth factor I on the immune system of aged female monkeys. Endocrinology 137: 1071-1079
40. Heijligenberg R., Sauerwein H. P., Brabant G., Endert E., Hommes M. J. and Romijn J. A. (1996) Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 81: 4028-4032
41. Pericle F., Pinto L. A., Hicks S., Kirken R. A., Sconocchia G., Rusnak J. et al. (1998) HIV-1 infection induces a selective reduction in STAT5 protein expression. J. Immunol. 160: 28-31
42. Murphy W. J., Tsarfaty G. and Longo D. L. (1992) Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myclosuppressive effects of azidothymidine. Blood 80: 1443-1447
43. Laurence J., Grimison B. and Gonenne A. (1992) Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood 79: 467-472
44. Mulligan K., Grunfeld C., Hellerstein M. K., Neese R. A. and Schambelan M. (1993) Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 77: 956-962
45. Krentz A. J., Koster F. T., Crist D. M., Finne K., Johnson L. Z., Boyle P. J. et al. (1993) Anthropometric, metabolic and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J. Acquir. Immune Defic. Syndr. 6: 245-251
46. Hirschfeld S. (1996) Use of human recombinant growth hormone and human recombinant insulin-like growth factor-I in patients with immunodeficiency virus infection. Horm. Res. 46: 215-221
47. Neidhart M. and Larson D. F. (1990) Freund's complete adjuvant induces ornithine decarboxylase activity in the central nervous system of male rats and triggers the release of pituitary hormones. J. Neuroimmunol. 26: 97-105
48. Lang C. H., Pollard V., Fan J., Traber D. L., Frost R. A., Gelato M. C. and Prough D. S. (1997) Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. Am. J. Physiol. 273: R371-R378
49. Redondo M., Rubio V., de la Pena A. and Morell M. (1997) The effects of the degree of surgical trauma and glucose load on concentration of thyrotropin, growth hormone and prolactin under enflurance anaesthesia. Horm. Metab. Res. 29: 66-69
50. Ertel W., Kremer J. P., Kenney J., Steckholzer U., Jarrar D., Trentz P. et al. (1995) Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85: 1341-1347
51. Bluet-Pajot M. T., Mounier F., Slama A., Videau C., Kordon C., Epelbaum J. et al. (1996) The increase in growth hormone secretion in experimentally induced arthritic rats is an adaptive process involved in the regulation of inflammation. Neuroendocrinology 63: 85-92
52. Zhu X. H., Zellweger R., Ayala A. and Chaudry I. H. (1996) Prolactin inhibits the increased cytokine gene expression in Kupffer cells following haemorrhage. Cytokine 8: 134-140
53. Jarrar D., Wolf S. E., Jeschke M. G., Ramirez R. J., DebRoy M., Ogle C. K. et al. (1997) Growth hormone attenuates the acute-phase response to thermal injury. Arch. Surg. 132: 1171-1175
54. Bentham J., Rodriguez-Arnao J. and Ross R. J. (1993) Acquired growth hormone resistance in patients with hypercatabolism. Horm. Res. 40: 87-91
55. Wojnar M. M., Fan J., Frost R. A., Gelato M. C. and Lang C. H. (1995) Alterations in the insulin-like growth factor system in trauma patients. Am. J. Physiol. 268: R970-R977
56. Klein G. L., Wolf S. E., Langman C. B., Rosen C. J., Mohan S., Keenan B. S. et al. (1998) Effects of therapy with recombinant human growth hormone on insulin-like growth factor system components and serum levels of biochemical markers of bone formation in children after severe burn injury. J. Clin. Endocrinol. Metab. 83: 21-24
57. Ziegler T. R. and Leader I. (1994) Adjunctive human growth hormone therapy in nutrition support: potential to limit septic complications in intensive care unit patients. Semin. Respir. Infect. 9: 240-247
58. Van den Berghe G. and de Zegher F. (1996) Anterior pituitary function during critical illness and dopamine treatment. Crit. Care Med. 24: 1580-1590
59. Steinberg A. D. (1994) Mechanisms of disordered immune regulation. In: Basic and Clinical Immunology, pp. 380-411, Stites D. P., Terr A. I. and Parslow T. G. (eds), Prentice-Hall, New York
60. Wilder R. L. (1995) Neuroendocrine-immune system interactions and autoimmunity. Annu. Rev. Immunol. 13: 307-338
61. Petri M., Howard D. and Repke J. (1991) Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience. Arthritis Rheum. 34: 1538-1545
62. Buskila D., Lorber M., Neumann L., Flusser D. and Schoenfeld Y. (1996) No correlation between prolactin levels and clinical actibity in patients with systemic lupus erythematosus. J. Rheumatol. 23: 629-632
63. Huang C. M. and Chou C. T. (1997) Hyperpralactinemia in systemic lupus erythematosus. Chuang Hua I Hsueh Tsa Chih (Taipeh) 59: 37-41
64. Neidhart M. (1996) Elevated serum prolactin or elevated prolactin cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J. Rheumatol. 23: 476-481
65. McMurray R. W., Allen S. H., Braun A. L., Rodriguez F. and Walker S. E. (1994) Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease. J. Rheumatol. 21: 843-850
66. Weidensaul D., Vassa N., Luger A., Walker S. E. and McMurray R. W. (1994) Primary antiphospholipid antibody syndrome and microscopic polyarteritis in the puerperium: a case report. Int. Arch. Allergy Appl. Immunol. 103: 311-316
67. Neeck G. and Michels H. (1996) Endocrine aspects of paediatric rheumatic diseases. Baillière's Clin. Rheumatol. 10: 349-363
68. Allen R. C., Jimenez M. and Cowell C. T. (1991) Insulin-like growth factor and growth hormone secretion in juvenile chronic arthritis. Ann. Rheum. Dis. 50: 602-606
69. McMurray R. W., Allen S. H. Pepmueller P. H., Keisler D. and Cassidy J. T. (1995) Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. J. Rheumatol. 22: 1577-1580
70. Ferrari C., Boghen M., Paracchi A., Rampini P., Raiteri F., Benco R. M. et al. (1983) Thyroid immunity in hyperprolactinaemic disorders. Acta Endocrinol. 104: 35-41
71. Kira J.-I., Harada M., Yamaguchi Y., Shida N. and Goto I. (1991) hyperprolactinemia in multiple sclerosis. J. Neurol. Sci. 102: 61-66
72. Reder A. T. and Lowy M. T. (1993) Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. J. Neurol. Sci. 117: 192-196
73. Garber J. R. and Hedley-White E. T. (1995) A 44-year old woman with headache, blurred vision, and an intrasellar mass. N. Engl. J. Med. 333: 441-447
74. Karanth S. and McCann S. M. (1991) Anterior pituitary hormone control by interleukin 2. Proc. Natl. Acad. Sci. 88: 2961-2965
75. Ray D. and Melmed S. (1997) Pituitary cytokine and growth factor expression and action. Endocr. Rev. 18: 206-228